All
Phase 3 Trial in Prostate Cancer Subset Discontinued Due to Lack of Survival Benefit
January 26th 2023A data monitoring committee recommended to stop the phase 3 trial in metastatic hormone-sensitive prostate cancer due to a lack of progression-free survival and overall survival with combination therapy.